Table 1.

Clinical characteristics and initial presentations of six patients with COVID-19 complicated by invasive aspergillosis who received tocilizumab.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age	72	53	61	63	61	77
Sex	Male	Male	Male	Male	Male	Female
Weight (kg)	77	73	70	53	64	66
Tobacco exposure	Current smoker	Never smoked	Current smoker	Never smoked	Former smoker	Never smoked
Comorbidities	DM, HbA1c: 6.6% Wegner granulomatosis	DM, HbA1c: 9.2%	DM, HbA1c: 11% HTN	DM, HbA1c: 9.4% HTN	COPD	DM, HbA1c: 6.4%
COVID-19 symptoms	Dyspnea, cough	Cough, myalgia	Cough, fever, dyspnea	Cough, fever, diarrhea	Fever, dyspnea, cough	Cough, dyspnea
Time from symptom onset to diagnosis (day(s))	3	2	4	1	1	1
APACHE II scores	23	11	13	26	18	31

Note: DM: diabetes mellitus; HbA1c: Hemoglobin A1c; COPD, chronic obstructive pulmonary disease; HTN: hypertension; APACHE II, Acute Physiology and Chronic Health Evaluation II.